April 24, 2008
Orexigen(R) Therapeutics Announces Completion Of Enrollment In Second Of Four Phase III Clinical Trials For Contrave(R)
ADVERTISEMENTS
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced completion of enrollment in NB-301, the largest of its Phase III clinical trials, for Contrave®, its lead obesity product candidate. This represents completion of enrollment in the second of four Phase III trials of Contrave.
Spread the word
Leave a Comment